Search for content, post, videos

New CMO for Oncos Therapeutics

Finnish Oncos Therapeutics Ltd  has appointed Dr Magnus Jaderberg, M.D, Ph.D, as Chief Medical Officer.

Dr Jaderberg joined Oncos Therapeutics on June 1, 2014.

“We are very happy to announce the recruitment of Magnus to our team. He will bring strategic expertise and knowledge to our prioritized research and clinical development of novel cancer immune therapies”, commented Frans Wuite, M.D., President and CEO of Oncos Therapeutics in a press release.

Jaderberg Oncos TherapeuticsAccording to Oncos Therapeutics, Dr Jaderberg is a pharmaceutical physician with more than 25 years’ experience in various R&D functions, including clinical research, medical affairs, pharmacovigilance, strategic product development, health economics and general management. His therapeutic area expertise includes immunology, oncology and infectious diseases. His immunotherapy expertise includes Yervoy (ipilimumab), Enbrel (etanercept), Torisel (temsirolimus), Orencia (abatacept), Rapamune (sirolimus) and Nulojix (belatacept). He has also studied medicine at the Karolinska Institute, Stockholm, Sweden, and is registered to practise medicine in Sweden and the UK. He was honorary lecturer in drug development at King’s College, London between 2003 and 2009, and he is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom.

Before joining Oncos Therapeutics Dr Jaderberg has held senior position roles at national, European and global level at GlaxoSmithKline, Pharmacia, Wyeth and Bristol Myers Squibb (BMS). His most recent position was as Chief Medical Officer, at BMS Europe.

 

Leave a Reply

Your email address will not be published. Required fields are marked *

two + 12 =